Literature DB >> 20040915

Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil".

Jérôme Dumortier1, Emiliano Giostra, Soraya Belbouab, Isabelle Morard, Olivier Guillaud, Laurent Spahr, Olivier Boillot, Laura Rubbia-Brandt, Jean-Yves Scoazec, Antoine Hadengue.   

Abstract

OBJECTIVES: Fatty liver disease is a potential long-term complication of liver transplantation (LT). We therefore aimed to determine the prevalence and risk factors of liver steatosis in a large population of adult post-LT patients.
METHODS: We evaluated the clinical, biological, histological, and evolutive features of patients with a diagnosis of steatosis made at liver biopsy examination during post-LT follow-up. Risk factors were analyzed by univariate and multivariate analysis.
RESULTS: In total, 1,596 liver biopsies from 599 patients were available. Recurrent liver disease was present in 178 patients. A histological diagnosis of steatosis was made in 131 (31.1%) of the remaining 421 patients (51.1% had normal liver tests): 53% had grade 1, 31% grade 2, and 16% grade 3 steatosis. Perisinusoidal fibrosis was present in 38 patients (29.0%). Histological lesions were consistent with the diagnosis of non-alcoholic steatohepatitis (NASH) in 5 patients (3.8%). At the end of follow-up, cirrhosis or extensive fibrosis was observed in 3 patients (2.25%). Multivariate analysis showed that seven factors (post-LT obesity, tacrolimus-based regimen, diabetes mellitus, hyperlipidemia, arterial hypertension, alcoholic cirrhosis as primary indication for LT, and pre-transplant liver graft steatosis) were risk factors for post-LT steatosis. When zero, one, two, three, four, five, and six factors were present, steatosis occurred in 6.0, 12.0, 22.1, 29.9, 65.5, 81.5, and 100.0%, respectively.
CONCLUSIONS: Liver steatosis is a frequent late complication of LT; its development depends on a combination of host and graft factors. LT is therefore an interesting model to study the natural history and the determinants of liver steatosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20040915     DOI: 10.1038/ajg.2009.717

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  46 in total

Review 1.  Posttransplant metabolic syndrome in children and adolescents after liver transplantation: a systematic review.

Authors:  Emily Rothbaum Perito; Audrey Lau; Sue Rhee; John P Roberts; Philip Rosenthal
Journal:  Liver Transpl       Date:  2012-09       Impact factor: 5.799

Review 2.  Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances.

Authors:  Adnan Said
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

3.  Incidence of Recurrent NASH-Related Allograft Cirrhosis.

Authors:  Shelly Kakar; Mohannad Dugum; Ricardo Cabello; Abhinav Humar; Jawad Ahmad; Shahid M Malik
Journal:  Dig Dis Sci       Date:  2018-12-17       Impact factor: 3.199

Review 4.  Liver transplantation and nonalcoholic fatty liver disease.

Authors:  Kymberly D Watt
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-09-25

5.  MR spectroscopy as a tool for in vivo determination of steatosis in liver transplant recipients.

Authors:  Milan Hájek; Monika Dezortová; Dita Wagnerová; Antonín Skoch; Luděk Voska; Irena Hejlová; Pavel Trunečka
Journal:  MAGMA       Date:  2011-07-10       Impact factor: 2.310

6.  Hepatic steatosis after pediatric liver transplant.

Authors:  Emily R Perito; Tabitha Vase; Rageshree Ramachandran; Andrew Phelps; Kuang-Yu Jen; Robert H Lustig; Vickie A Feldstein; Philip Rosenthal
Journal:  Liver Transpl       Date:  2017-07       Impact factor: 5.799

Review 7.  Preventive Strategies for Nonalcoholic Fatty Liver Disease After Liver Transplantation.

Authors:  Narendra S Choudhary; Sanjiv Saigal
Journal:  J Clin Exp Hepatol       Date:  2019-05-30

Review 8.  NAFLD and liver transplantation: Current burden and expected challenges.

Authors:  Raluca Pais; A Sidney Barritt; Yvon Calmus; Olivier Scatton; Thomas Runge; Pascal Lebray; Thierry Poynard; Vlad Ratziu; Filomena Conti
Journal:  J Hepatol       Date:  2016-07-30       Impact factor: 25.083

Review 9.  Liver transplantation and non-alcoholic fatty liver disease.

Authors:  Petros Zezos; Eberhard L Renner
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

10.  Posttransplant metabolic syndrome in the withdrawal of immunosuppression in Pediatric Liver Transplant Recipients (WISP-R) pilot trial.

Authors:  E R Perito; S Mohammad; P Rosenthal; E M Alonso; U D Ekong; S J Lobritto; S Feng
Journal:  Am J Transplant       Date:  2015-02-03       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.